Suboxone Lawsuit for Tooth Decay

Our law firm is handling Suboxone lawsuits. Our lawyers are bringing these tooth decay lawsuits because the defendants knew their drug was causing severe tooth decay and other dental injuries and told no one.

Yes, they finally put a warning on in 2022. But every Suboxone lawsuit that is being filed is for victims of tooth decay, broken teeth, and other dental injuries that flow from Suboxone, who used the product before 2022 and were blindsided with this risk for no good reason.

Potential dental issues with Suboxone include:

• Tooth decay
• Tooth loss and extraction
• Infections
• Cracked teeth
• Cavities
• Root canal
• Dental caries (loss of enamel, dentine, etc.)
• Crown or crown replacement

If you are a victim, you may be eligible for compensation through a Suboxone lawsuit payout. Our lawyers believe that the defendants in these cases will be forced to pay reasonable settlement amounts to patients who used this product and suffered severe dental injuries.

Our Suboxone lawyers are actively investigating claims against the drug manufacturers for their failure to provide adequate warnings about the risks of severe tooth decay and other dental problems associated with Suboxone in 2024.

In 2024, our lawyers are taking cases for patients who were prescribed Suboxone in these states (we need to add Florida and Michigan to this list, too – we are now taking new Suboxone lawsuits in both states).

Find out if you qualify for a Suboxone lawsuit payout by contacting our law firm online to schedule a case review. You can also reach out to our product liability attorneys at any time by calling 800-553-8082 or contacting us online.

No fees or expenses are involved – ever – unless we successfully secure a settlement amount or jury payout for you.

Suboxone Lawsuit News and Updates

Our lawyers are committed to keeping victims updated on the latest events in this litigation.

April 18, 2024:

A new Suboxone lawsuit filed last week involves a Westchester County, New York, plaintiff who has experienced significant dental damage, attributed to the use of prescription Suboxone film. Initially prescribed the medication for opioid addiction, the plaintiff was not warned of the potential for serious dental erosion and decay. Despite adhering to medical advice, the plaintiff now faces permanent tooth damage and has undergone extensive dental work to address the harm caused by the medication. The lawsuit seeks compensation for the injuries and damages incurred as a result of using Suboxone film.

April 17, 2024:

Indivior advocates for a discovery phase that prioritizes general causation due to its pivotal role in the litigation’s outcome.

Indivior’s legal team asserts that if general causation cannot be reliably established through scientific evidence, it would render other aspects of the cases unnecessary and inefficient. This strategic approach is designed to conserve resources by averting extensive discovery and litigation efforts that could potentially be futile if general causation is not proven.

Indivior is right that general causation must be proved, or the rest of the case is moot. Are there other personal injury MDLs where this is also true? Yes, every single one.

Indivior draws upon past legal precedents in which courts have ordered discovery to commence with general causation, citing this method as a way to streamline the process and avoid unnecessary legal expenses. Specifically, they cite four cases where this was kinda, sorta the path out of zillions of MDLs over the years.

One huge distinction between the Suboxone lawsuits and those isolated cases is that the manufacturer already has put a warning on the product and has not sought to have it removed.

The update to the Suboxone warning label to include tooth decay is indicative of general causation in the litigation concerning its link to dental injuries. This change in labeling is an acknowledgment by the manufacturer and regulatory authorities of a plausible link between Suboxone use and dental issues, based on observed data and reported cases.

It is a big deal that the warning on this product ultimately changed. A warning label change significantly impacts the arguments surrounding general causation. It is evidence that the manufacturer was aware of potential harms caused by their product, which clearly suggests that there is a scientifically reasonable basis for believing that the product can cause the injury claimed. The label change implies that there have been enough reports or findings to warrant caution to users about specific health risks, in this case, dental injuries.

What a delay would do for Indivior is give them a chance to delay the litigation. After we prove general causation, we would be nowhere on getting individual lawsuits ready for trial. Endless delays frustrate plaintiffs and would push them into being willing to accept lower Suboxone settlement amounts.

Adopting a dual-track discovery approach for both specific and general causation simultaneously can significantly enhance litigation efficiency by ensuring that individual claims are processed concurrently with broader causation issues. This method prevents the stalling of personal adjudications and alleviates the undue burden on plaintiffs, who otherwise might face prolonged delays and increased financial and emotional strain.  Such a plan allows for a more dynamic allocation of resources, potentially minimizing redundancy and ensuring that all aspects of each case receive timely and appropriate attention. By addressing individual specifics alongside general causation, the court can streamline proceedings, reduce bottlenecks, and facilitate a quicker resolution.

April 10, 2024: Is your Suboxone lawyer calling you? Please return the call. Many attorneys will soon begin dropping clients they cannot reach as they race to file claims in the MDL in states with a two-year statute of limitations.

April 1, 2024: Over the last month, 30 new cases have been added to the new Suboxone class action MDL, which now has 44 pending cases.

March 25, 2024: Four new Suboxone suits were transferred to the MDL today.

March 19, 2024: In Case Management Order No. 3, Judge Calabrese establishes protocols for the direct filing and service of process. Defendants have agreed to waive formal service of summons for cases in this MDL, except for Reckitt Benckiser Healthcare (UK) Ltd., which has agreed to abate the issue of service waiver. Defendants are required to establish an email address to accept service of complaints, facilitating an expedited process. However, this does not apply to Reckitt Benckiser, who clearly wants to be difficult.  So traditional service methods may still be required.

Importantly, the order allows for the direct filing of Suboxone lawsuits. Direct filing in an MDL allows plaintiffs to file their lawsuits directly into the centralized proceeding, bypassing the initial filing in their local jurisdiction and the subsequent transfer process.

The order also confirms that directly filing an action does not determine the applicable choice of law and does not require the application of Ohio’s choice of law rules. Instead, the choice of law will be determined as if the case were originally filed in the designated “Original Venue” and then transferred to the MDL. Upon completion of pretrial proceedings, cases will be presumptively transferred back to their original venues for trial, unless otherwise objected to or agreed upon by the parties.

March 11, 2024: We put up a pretty new and pretty comprehensive Suboxone lawsuit video today that explains where we are in the litigation and talks about expected settlement amounts.

March 8, 2024: The first Suboxone status conference was held yesterday.  Not much to report but we should shortly have the ability to direct file in the MDL and hopefully graduate to a short-form complaint to make filing claims a lot easier.

The impression lawyers have coming out of the hearing is that Judge Calabrese will be eager to push this litigation forward.  That is good news for everyone.

March 7, 2024: The defendants are proposing a gradual approach to the process of pretrial discovery in the Suboxone litigation.  They want an initial phase focusing specifically on establishing general causation.

In other words, the Suboxone defendants want first to gather evidence to determine if there is a general link between the defendant’s actions or product and the alleged harm. On the other hand, the plaintiffs are against splitting the discovery process into different phases, particularly when it comes to investigating general causation.

Why?  Two reasons.  First, general causation is a lock in these cases. We have a warning on the subject of this litigation.  Second, bifurcated litigation slows down the path to getting trial dates which slows down the path to settlement.

March 5, 2024: A federal judge in the US District Court of the Eastern District of Pennsylvania has approved a $385 million settlement between a group of direct purchasers and Indivior Inc., the maker of Suboxone, an opioid addiction treatment.

This is not a tooth decay class action lawsuit alleging personal injuries.  This is an entirely different Suboxone lawsuit. The settlement resolves claims that Indivior abused its monopoly over Suboxone.  The lawsuit, initiated nearly a decade ago, centered on Indivior’s decision to switch Suboxone from a tablet to a sublingual film in 2010, with plaintiffs alleging anticompetitive motives.  Indivior had previously settled with 42 states’ attorneys general for approximately $102.5 million and with a plaintiff class of end-payors for $30 million.

March 4, 2024: A new Suboxone lawsuit was filed Friday on behalf of a Pennsylvania woman who was prescribed Suboxone film in 2016 to treat an opioid addiction that began after a wrist surgery nearly ten years before.  She switched to Suboxone film in 2019.  Her tooth decay symptoms began in 2020.  Of course, neither she nor her doctors understood that her dental complications were from Suboxone because there was no warning on the product until 2022.

March 1, 2024: The newly created Suboxone tooth decay class action MDL currently has a total of 51 pending cases. This is going to be a fast-growing MDL so look for this number to go up very quickly over the next few months.

February 19, 2024: A new Suboxone lawsuit was filed in federal court last week. A resident of Washington County, Pennsylvania, filed suit following severe dental damage attributed to the use of Suboxone film she used for opioid use disorder management.

As all of these suits do, this lawsuit emphasizes the absence of adequate warnings about the potential for dental erosion and decay associated with the medication, despite the FDA mandating a new warning label in June 2022 for all buprenorphine medications that dissolve in the mouth. This label change highlighted the risk of dental issues, a warning not deemed necessary for other buprenorphine formats like injectables or patches.

February 13, 2024:  MDL No. 3092 is moving forward now.  Case Management Order No. 1 for the Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, as this litigation will be called, kicks off the litigation and outlines the initial steps for organizing and managing these consolidated lawsuits.

Nothing surprising in this order from Judge J. Philip Calabrese,   Here are the key points summarized:

1. Initial Status Conference: Scheduled for March 7, 2024, at the Carl B. Stokes U.S. Courthouse in Cleveland, Ohio. This is a preliminary conference, and parties are not required to submit a Rule 26(f) Report beforehand.
2. Attendance Requirements:
   • Counsel for all parties do not need to attend in person, and groups with similar interests are encouraged to appoint a single attorney to represent them collectively at the conference.
   • Attendance via phone is allowed, but notice must be given to the Court’s MDL Clerk by March 4, 2024.
   • Counsel seeking leadership roles should be present in person, as those not in attendance won’t have the opportunity to speak at this conference.
3. Participation of Other Counsel: Attorneys representing clients not currently part of the litigation but who may be joined later are invited to attend or participate.
4. Pre-Conference Submissions:
   • By March 1, 2024, parties must submit a joint memorandum discussing various issues, including case categorization, anticipated case numbers and types, document repository creation, discovery protocols, and more.
5. Leadership Structure:
   • The court plans to appoint leadership counsel for plaintiffs, considering criteria such as cooperation, commitment, experience, and resources.
   • Applications for leadership positions are due by March 1, 2024.
6. Plaintiffs’ Separate Submission: Also by March 1, 2024, plaintiffs’ counsel must submit a memorandum detailing the proposed leadership structure, responsibilities, and the management of a common benefit fee and expense fund.
7. Stays on Pleadings and Discovery: Deadlines for defendants to respond to complaints and all current disclosures, discovery, and motions to dismiss are stayed until the status conference, where further directions will be discussed.
8. Application to Later-Filed Cases: This order applies to all cases later filed in, transferred to, or removed to this court as part of the MDL.
9. Admission of Counsel: Attorneys of record in transferred actions may continue to represent their clients without the need for a pro hac vice motion, but must maintain an electronic filing account. This is a blessing.

This order sets the procedural groundwork for managing the litigation, including initial conference logistics, leadership structure, and preliminary case management protocols.

You will see more lawyers getting involved, and, more importantly, we are increasing our settlement payout estimates. The reality is that the warning was changed for a reason – Suboxone causes tooth decay. No one disagrees with this, an incredible luxury in proving any civil lawsuit.

January 30, 2024:  All along we have told you we do not support a Suboxone recall. Instead, what our Suboxone lawyers are saying is that patients need to know the dental injury risks to make an informed choice and to engage in dental hygiene to control that risk.

The findings of a new study suggests that pregnant women are a group that should be talking to their doctor about possibly choosing Suboxone over methadone. Why? The study found that women seeking treatment for opioid addiction may face a higher risk of delivering a child with birth defects if they use methadone, compared to the use of Suboxone or other buprenorphine drugs.

January 26, 2024: Today, the JPML Panel met to discuss whether to consolidate the Suboxone lawsuits. Our lawyers believe the Panel will rule next month to consolidate these cases in a new Suboxone class action lawsuit.

January 23, 2024:  In 2024, our lawyers are accepting new Suboxone lawsuits in these states (and now, in April 2024, Michigan):

January 16, 2024: A new Suboxone lawsuit was filed on Friday. The plaintiff, a resident and citizen of  Pennsylvania, experienced dental damage directly caused by using the Suboxone film prescribed by the Defendants.

In 2013, a physician prescribed Suboxone film to Plaintiff for the treatment of opioid use disorder. Of course, neither Plaintiff nor Plaintiff’s physicians were informed of the significant risk of dental erosion and decay associated with Suboxone film. Plaintiff now suffers from permanent tooth damage and has undergone extensive dental procedures to address the damage caused by Suboxone film.

January 11, 2024:  Our lawyers have not seen any new Suboxone lawsuits since the one filed by our legal team at the end of last year. More will be filed before the MDL hearing at the end of the month to show the MDL Panel that the volume of cases justifies a Suboxone class action lawsuit.

January 4, 2023: What is crazy is that the medication guide for Suboxone film does not include warnings about certain tooth decay risks as a potential side effect of this drug formulation. It is in the prescribing information, but Indivior apparently does not take it seriously enough – even with all of these Suboxone dental injury lawsuits – to put it in the medication guide. It is hard to understand what Indivior is thinking.

January 2, 2023: As we head into the hearing later this month on forming a Suboxone class action MDL, there are at least 15 Suboxone tooth decay cases pending in 5 different federal districts nationwide. That may seem like a small number, but there are thousands more Suboxone cases under active investigation and soon to be filed by lawyers across the country.

December 13, 2023: The defendants in the Suboxone tooth decay lawsuits recently filed a response to the request for class action MDL consolidation. In the response, the Suboxone defendants actually agreed with the motion to create a new Suboxone class action MDL. They request that the MDL be assigned to Judge Philip Calabrese in the Northern District of Ohio. The Suboxone MDL will likely be established next month.

December 7, 2023: We have a new video proving the latest news in the effort to create a Suboxone class action lawsuit and how an MDL will put real settlement pressure on Indivior. We also talk about the main reason our lawyers believe most victims bringing a Suboxone lawsuit will have a strong case.

November 27, 2023: Legal representatives for the plaintiffs have petitioned the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate all federal lawsuits related to Suboxone into a single multidistrict litigation (MDL).

So, this is the effort to form a class action lawsuit. Plaintiffs ask that every federal Suboxone lawsuit be transferred to a federal court in Ohio. What would this do? It would simplify and expedite pretrial processes and push Indivior to offer reasonable settlement amounts (down the road, anyway). Presently, these lawsuits are scattered across various federal districts. Forming an MDL class action lawsuit would provide a more efficient way to handle these cases, which all share similar foundational allegations.

November 3, 2023: In just the last two weeks, fourteen new Suboxone product liability lawsuits have been filed in federal courts against the manufacturer, Indivior. Eight of them were filed in the Northern District of Ohio, which has the most pending Suboxone cases of any district.

November 2, 2023: A man in Wood County, Ohio, filed a Suboxone lawsuit after suffering from dental injuries after using Suboxone film.

Like most of the victims who call our law firm, he developed an addiction to opioids. His doctor prescribed Suboxone to manage the addiction. As a result of the prescribed usage of Suboxone film, the plaintiff now alleges he suffers from permanent tooth damage.

His Suboxone tooth decay lawsuit seeks damages for the substantial dental procedures he has undergone and for the pain and suffering these injuries have caused him.

October 30, 2023: Indivior, the manufacturer of Suboxone, will be fighting a two-front litigation battle. While the number of tooth decay suboxone lawsuits continues to grow, Indivior will also defend a false claims act lawsuit accusing the company of an illegal kickback scheme. Last week, a federal judge rejected Indivior’s motion to dismiss that case and allowed it to proceed.

October 24, 2023: The maker of Suboxone, Indivior, has now agreed to pay another $385 million to settle an antitrust lawsuit accusing the company of illegally suppressing generic competition.

The lawsuits claim that Indivior introduced the dissolving film tab version of Suboxone just as its patent on the original pill version was about to expire to block competition from generic Suboxone tablets. Indivior already paid $900 million to settle a similar lawsuit the states and the federal government brought.

October 16, 2023: A man from Geauga County, Ohio, became the latest plaintiff to file a Suboxone tooth decay lawsuit in federal court King v. Indivior, Inc, et al. 1:23-cv-01924 (N.D. Ohio).

According to the Complaint, the plaintiff became addicted to opioids after being prescribed them by his doctor. The plaintiff was eventually prescribed Suboxone to treat his addiction. After just 16 months on Suboxone, the plaintiff began to suffer severe tooth decay and eventually had to have several teeth extracted permanently.

The Complaint alleges that neither the plaintiff nor his doctor knew Suboxone caused tooth decay.

Suboxone

Suboxone is a medication primarily used in the treatment of opioid addiction, and it has been an assistance to doctors trying to get patients off opioids.

Suboxone combines two active ingredients: buprenorphine and naloxone. Buprenorphine is a partial opioid agonist, which means it activates the same receptors in the brain as opioids but to a lesser degree, reducing withdrawal symptoms and cravings while preventing the intense high associated with full opioid agonists like heroin or prescription painkillers.

Naloxone, on the other hand, is an opioid antagonist that reverses the effects of opioids and can precipitate withdrawal symptoms if misused. Suboxone comes in the form of sublingual films or tablets, and it’s typically administered as part of a comprehensive treatment program that includes counseling and therapy.

While Suboxone has admittedly had some success in helping individuals manage opioid addiction and transition towards a drug-free life, it’s not without its risks and side effects. Common side effects may include nausea, headache, sweating, constipation, and sleep disturbances.

These side effects are generally manageable and are outweighed by the benefits of reducing opioid dependence. You can help manage them because… the companies that make and distribute the drug warn about these risks. So doctors and patients know of the risks and make an informed choice. So you would think…

Suboxone Lawsuits

Our law firm is handling Suboxone lawsuits. Our lawyers are bringing these tooth decay lawsuits because the defendants knew their drug was causing severe tooth decay and dental injuries and told no one.

Yes, they finally put a warning on in 2022. But every Suboxone lawsuit that is being filed is for victims of tooth decay, broken teeth, and other dental injuries that flow from Suboxone, who used the product before 2022 and who were blindsided with this risk for no good reason.

If you are a victim, you may be eligible for compensation through a Suboxone lawsuit payout. Our lawyers believe that the defendants in these cases will be forced to pay reasonable settlement amounts to patients who used this product and suffered severe dental injuries.

Again, our Suboxone lawyers are actively investigating claims against the drug manufacturers for their failure to provide adequate warnings about the risks of severe tooth decay and other dental problems associated with Suboxone. Our legal team began bringing Suboxone lawsuits in 2023, and our team will bring many more suits in 2024.

No fees or expenses are involved – ever – unless we successfully secure a settlement amount or jury payout for you.

The Risk of Dental Injuries

Studies have indicated that Suboxone sublingual films, which dissolve under the tongue, may lead to tooth decay and other dental problems due to their acidic nature.

Extended exposure to this acidic medication can weaken tooth enamel and contribute to dental issues such as cavities, gum disease, and even tooth loss. These dental problems can be painful and may necessitate corrective dental procedures like fillings, extractions, or implants.

If you started taking Suboxone in 2023, you likely learned about this risk through discussions with your doctor or reading the package insert.

To manage this risk, patients can take extra care of their teeth through regular brushing, flossing, and using fluoride toothpaste and mouthwash to strengthen tooth enamel. Dietary adjustments, like reducing sugary food and beverage consumption while ensuring a calcium and vitamin D-rich diet, can also help maintain strong teeth.

However, if you used the product before the 2022 warning, you probably did not know about this risk. If you suffered severe tooth decay or other dental injuries and were unaware of the risk, you are an ideal candidate for a Suboxone lawsuit.

The Core of Every Suboxone Lawsuit – Failure to Warn

If you are taking Suboxone in 2023, you likely know of this risk because you discussed it with your doctor or read it on the package insert. What can they do? They can be extra careful with their teeth. Patients could have paid extra attention to their oral hygiene practices. This includes regular brushing and flossing to maintain healthy teeth and gums. Using fluoride toothpaste and mouthwash can also help strengthen tooth enamel.

Patients can also adjust their dietary habits. This could involve reducing the consumption of sugary foods and beverages, which can contribute to tooth decay. A diet rich in calcium and vitamin D can help maintain strong teeth.

Patients can also, not for nothing, choose another drug than Suboxone to deal with withdrawal.

No Warning Before 2022

But if you took the product before the warning in 2022, you likely did not know of this risk. If you did not know of the risk and you suffered severe tooth decay or other dental injuries, you are a prime candidate for a Suboxone lawsuit.

In June 2022, the defendants finally updated the prescribing information for Suboxone film to include warnings about the risk of dental issues.

The Suboxone Study That Broke the Camel’s Back

A 2022 study confirmed what Suboxone lawyers had already known – Suboxone causes dental injuries. Researchers looked at three groups of people who used different medications: sublingual buprenorphine/naloxone, transdermal buprenorphine, and oral naltrexone. They found that the group using sublingual buprenorphine/naloxone had a higher risk of dental problems compared to the other two groups.

Specifically, they found that the group using sublingual buprenorphine/naloxone had more dental issues, such as cavities and tooth loss. The risk of dental problems was 1.42 times higher compared to those using transdermal buprenorphine and 1.67 times higher compared to those using oral naltrexone.

The incidence rates of dental caries or tooth loss were also significantly higher with sublingual buprenorphine/naloxone at 8.2 per 1000 person-years, compared to 3.5 for transdermal buprenorphine and 3.8 for oral naltrexone. That is a huge difference. For dental caries or tooth loss, the HRs were 1.57 for sublingual buprenorphine/naloxone versus transdermal buprenorphine and 1.71 versus oral naltrexone.

Why? Researchers think the acidic nature of sublingual buprenorphine/naloxone might be causing these dental problems. People taking this medication are instructed to hold it under their tongue for a few minutes, which could expose their teeth to acid for extended periods.

What our Suboxone lawyers have been able to gather from all of this is that Suboxone sublingual films are notably acidic. We have known forever that acidity can contribute to tooth decay. When these films dissolve under the tongue, they introduce acidity to the mouth, weakening tooth enamel—the protective outer layer of teeth. As enamel erodes, the inner layer, dentin, becomes more exposed and vulnerable to decay.

Who Qualifies for a Suboxone Lawsuit in 2024?

Victims who used these sublingual films and developed dental problems such as severe tooth decay or loss, tooth extractions, broken teeth, and jaw bone injuries are potential plaintiffs. Our lawyers expect that if there is a Suboxone class action lawsuit and a settlement, there will be higher settlement amounts if you require dental implants, oral surgeries, or other escalated dental treatment.

Primary Defendants in Suboxone Lawsuits

Indivior, Inc. and Aquestive Therapeutics Inc. are the pharmaceutical companies that developed Suboxone, and Indivor is the primary drug manufacturer. Both of these companies are named as primary defendants in the Suboxone lawsuits. Neither of these companies is a household name like Pfizer. That is because these are not your typical “big pharma” companies. Instead, they are specialty or “boutique” pharmaceutical companies that focus on a specific segment of the drug industry.

Indivior’s entire business is specifically focused on developing and manufacturing buprenorphine-based drugs that are utilized in the treatment of opioid dependency. Until fairly recently, Indivior was a division of Reckitt Benckiser (Reckitt), a larger pharma company based in the United Kingdom. When the market for opioid dependency drugs started to explode about eight years ago, Reckitt cashed in on the potential profitability and spun off Indivior as a new publicly traded company. Reckitt owns a significant percentage of shares in Indivor and is typically named as a defendant in the Suboxone lawsuits.

Although all of the various companies related to Suboxone are generally named in these lawsuits, Indivior will assume primary liability. One thing that stands out about Indivior is that it already has a “rap sheet” with U.S. authorities. The DOJ recently indicted the Company for engaging in an illegal scheme to funnel patients to specific doctors who were prescribing Suboxone or other Indivior drugs. This matter was eventually resolved when Indivior agreed to pay $102 million in damages to 42 states.

Estimated Settlement Payout Value for Suboxone Lawsuits

Our mass tort attorneys estimate that successful Suboxone lawsuits involving tooth decay could have a settlement payout value range of around $30,000 to $150,000.

Trial value is a different story. The estimated jury payout for a Suboxone lawsuit that goes to trial could be millions of dollars. In a case like this, what could inflate jury awards is the possibility of punitive damages, and it sounds like, based on what Suboxone lawyers already know before we even get into pretrial discovery,  there is fertile ground for punitive damages in these cases.

Even if punitive damages are not awarded, the trial value of these cases would be much higher than their settlement value. What would be a reasonable estimate of the average jury verdict for a Suboxone compensation claim even without punitive damages? That question takes the word speculative to a whole new level. But our attorneys think the potential jury payouts for a Suboxone lawsuit would be $500,000 to $ 1 million. A case with a sympathetic plaintiff and good facts could fetch an even larger Suboxone payout.

All of this – jury predictions and settlement payout estimates – are very speculative. The Suboxone tooth decay lawsuits are still very new. We have not even gotten through the discovery phase in any of the cases, so many variables could potentially impact the viability of these cases. Our settlement compensation payout estimates are based on the assumption that these cases will be viable and successful. It is all very new, but our Suboxone lawyers have high hopes for these lawsuits.

Punitive Damages

Punitive damages may really drive Suboxone settlement amounts in this litigation. It is not a complex case to make here.

The defendants are alleged to have knowingly and consciously disregarded the safety of others. Specifically, it is claimed that they misled the medical community and the public with false or misleading information about Suboxone’s safety and effectiveness and did not provide adequate usage instructions or training. They allegedly downplayed, understated, or ignored the severe side effects and risks associated with Suboxone, particularly its potential to cause dental erosion and decay, despite being aware or should have been aware of these risks.

So plaintiffs will seek, in jurisdictions where the law allows, punitive damages by arguing that the defendants’ conduct was willful, intentional, and recklessly disregarded the rights and safety of consumers. The message to the jury: the defendants should be punished and deterred from similar conduct in the future.

If a jury accepts the ample evidence plaintiffs will present, it may award millions of dollars in jury compensation. Would verdicts like this drive Suboxone settlement payouts higher? Of course.

Suboxone Class Action Lawsuit

Right now, the Suboxone tooth decay lawsuits have a class action lawsuit (MDL) pending.

This will get certified late this month on February 2024. The size of the potential plaintiff field for this litigation is very large. Millions of people have become hooked on opioids over the last few decades, and all of these individuals could end up using Suboxone at some point. The percentage of individuals who suffer tooth decay when they use Suboxone is very high. So, it is hard to imagine litigation more ripe for a class action lawsuit.

How to Join the Suboxone Tooth Decay Lawsuit

Our national mass tort lawyers are looking for Suboxone cases across the country. Call us today at 800-553-8082 or contact us online for a free consultation.